Vacunación y riesgo de cáncer del cuello uterino invasivo

1.Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.

2. Global HPV vaccine introduction overview: projected and current national introductions, demonstration/pilot projects, gender-neutral vaccination programs, and global HPV vaccine introduction maps (2006–2022). 2019 (https://path.azureedge.net/media/documents/GlobalHPVVaccine IntroOverview_Nov2019.pdf).

3. Wang J, Ploner A, Sparén P, et al. Mode of HPV vaccination delivery and equity in vaccine uptake: a nationwide cohort study. Prev Med 2019;120:26-33.

4. Arbyn M, Xu L, Simoens C, MartinHirsch PP. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev 2018;5:CD009069.

5. Paavonen J, Naud P, Salmerón J, et al. Efficacy of human papillomavirus (HPV)- 16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301-14

 6. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27.

7. Drolet M, Bénard É, Boily MC, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2015;15: 565-80.

. Drolet M, Bénard É, Pérez N, Brisson M. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet 2019;394:497-509.

9. Garland SM, Kjaer SK, Muñoz N, et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clin Infect Dis 2016;63:519- 27.

10. Silverberg MJ, Leyden WA, Lam JO, et al. Effectiveness of catch-up human papillomavirus vaccination on incident cervical neoplasia in a US health-care setting: a population-based case-control study. Lancet Child Adolesc Health 2018;2:707-14.

11. Herweijer E, Sundström K, Ploner A, Uhnoo I, Sparén P, Arnheim-Dahlström L. Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: a population-based study. Int J Cancer 2016;138:2867-74.

12. Herweijer E, Sundström K, Ploner A, Uhnoo I, Sparén P, Arnheim-Dahlström L. Erratum: quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: a populationbased study. Int J Cancer 2017;141(1):E1-E4.

3. Leval A, Herweijer E, Ploner A, et al. Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study. J Natl Cancer Inst 2013;105: 469-74

 14. Luostarinen T, Apter D, Dillner J, et al. Vaccination protects against invasive HPVassociated cancers. Int J Cancer 2018;142: 2186-7.

15. National Swedish guidelines for cervical cancer prevention, diagnosis, and treatment. 2019. (In Swedish) (https://www.cancercentrum.se/globalassets/vara-uppdrag/prevention-tidig-upptackt/ gynekologisk-cellprovskontroll/ vardprogram/nationellt-vardprogram -cervixcancerprevention.pdf).

16. Ludvigsson JF, Almqvist C, Edstedt Bonamy A-K, et al. Registers of the Swedish total population and their use in medical research. Eur J Epidemiol 2016;31:125- 36

17. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol 2009;24:659-67.

18. The Public Health Agency of Sweden. Statistics for HPV vaccinations. 2019. (In Swedish) (https://www.folkhalsomyndigheten .se/folkhalsorapportering-statistik/ statistikdatabaser-och-visualisering/ vaccinationsstatistik/statistik-for-hpv -vaccinationer/).